Table 2.
Factors associated with rifampin-resistant Mycobacterium tuberculosis based on Xpert MTB/RIF assay
| Rifampin resistance | ||||
|---|---|---|---|---|
| Univariate | Multivariate | |||
| RR (95 % CI) | P | aRR (95 % CI) | P | |
| Age (years) | 0.99 (0.96–1.03) | 0.78 | --- | --- |
| Sex (male) | 0.58 (0.18–1.88) | 0.37 | --- | --- |
| Diabetesa | 3.11 (1.35–7.17) | <0.01 | 2.96 (1.30–6.74) | <0.01 |
| Previous TB Treatment | 3.52 (1.58–7.84) | <0.01 | 3.33 (1.53–7.22) | <0.01 |
| BCG Vaccination | 0.60 (0.26–1.36) | 0.22 | --- | --- |
| TB Symptoms (weeks)b | 1.00 (0.97–1.03) | 0.81 | --- | --- |
| QFT-G | 2.02 (0.50–8.22) | 0.33 | --- | --- |
| AFB | 3.60 (0.87–14.91) | 0.08 | 3.14 (1.03–9.58) | 0.05 |
Abbreviations: AFB Acid-fast bacilli sputum smear microscopy, BCG Bacille Calmette-Guérin, CI confidence interval, TB tuberculosis, QFT-G Quantiferon-TB Gold In-Tube, RR risk ratio, aRR adjusted risk ratio
aAccording to patient self-report
bTime (weeks) since initial onset of symptoms suggestive of TB, including persistent cough, fever, weight loss